Dystonia rating scales: Critique and recommendations

Movement Disorders

Volumn 28, Issue 7, 2013, Pages 874-883

  Albanese, Alberto ^a,b   Sorbo, Francesca Del ^b   Comella, Cynthia ^c   Jinnah, H A ^d   Mink, Jonathan W ^e   Post, Bart ^f   Vidailhet, Marie ^g   Volkmann, Jens ^h   Warner, Thomas T ⁱ   Leentjens, Albert F G ^j   Martinez Martin, Pablo ^k   Stebbins, Glenn T ^l   Goetz, Christopher G ^l   Schrag, Anette ^m  

^a UNIVERSITÀ CATTOLICA DEL SACRO CUORE   (Italy)

^b DEPARTMENT OF NEUROSURGERY   (Italy)

^c RUSH MEDICAL COLLEGE   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^f RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^g PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^h UNIVERSITY OF WÜRZBURG   (Germany)

ⁱ UNIVERSITY COLLEGE LONDON   (United Kingdom)

^j MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^k CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^l RUSH UNIVERSITY MEDICAL CENTER   (United States)

^m UNIVERSITY COLLEGE LONDON   (United Kingdom)

more..

Author keywords

Blepharospasm; Botulinum neurotoxins; Dystonias; Rating scales; Torticollis

Indexed keywords

ARM DYSTONIA; BLEPHAROSPASM; BLEPHAROSPASM DISABILITY INDEX; CERVICAL DYSTONIA; CERVICAL DYSTONIA IMPACT SCALE; CRANIOCERVICAL DYSTONIA QUESTIONNAIRE; DYSTONIA; FAHN MARSDEN DYSTONIA RATING SCALE; GENERALIZED DYSTONIA; HUMAN; OROMANDIBULAR DYSTONIA; PRIORITY JOURNAL; RATING SCALE; REVIEW; SPASMODIC DYSPHONIA; SYSTEMATIC REVIEW; TASK SPECIFIC DYSTONIA; TORONTO WESTERN SPASMODIC TORTICOLLIS RATING SCALE; VALIDITY; VOCAL PERFORMANCE QUESTIONNAIRE; VOICE DISORDER; VOICE HANDICAP INDEX;

EID: 84880771822     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25579     Document Type: Review

References (115)

1. Steeves TD, Day L, Dykeman J, Jette N, Pringsheim T. The prevalence of primary dystonia: a systematic review and meta-analysis. Mov Disord 2012;27:1789-1796.
2. Albanese A, Asmus F, Bhatia KP, et al. EFNS guidelines on diagnosis and treatment of primary dystonias. Eur J Neurol 2011;18:5-18.
3. Albanese A, Bhatia KP, Bressman SB, et al. Phenomenology and classification of dystonia: a consensus update. Mov Disord 2013;863-873.
4. Stamelou M, Edwards MJ, Hallett M, Bhatia KP. The non-motor syndrome of primary dystonia: clinical and pathophysiological implications. Brain 2012;135:1668-1681.
5. Hallett M, Benecke R, Blitzer A, Comella CL. Treatment of focal dystonias with botulinum neurotoxin. Toxicon 2009;54:628-633.
6. Cloud LJ, Jinnah HA. Treatment strategies for dystonia. Expert Opin Pharmacother 2010;11:5-15.
7. Goetz CG, Tilley BC, Shaftman SR, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 2008;23:2129-2170.
8. The Unified Parkinson's Disease Rating Scale (UPDRS): status and recommendations. Mov Disord 2003;18:738-750.
9. Jankovic J, Kenney C, Grafe S, Goertelmeyer R, Comes G. Relationship between various clinical outcome assessments in patients with blepharospasm. Mov Disord 2009;24:407-413.
10. Roggenkamper P, Jost WH, Bihari K, Comes G, Grafe S. Efficacy and safety of a new botulinum toxin type A free of complexing proteins in the treatment of blepharospasm. J Neural Transm 2006;113:303-312.
11. Wabbels B, Reichel G, Fulford-Smith A, Wright N, Roggenkamper P. Double-blind, randomised, parallel group pilot study comparing two botulinum toxin type A products for the treatment of blepharospasm. J Neural Transm 2011;118:233-239.
12. Jankovic J, Comella C, Hanschmann A, Grafe S. Efficacy and safety of incobotulinumtoxinA (NT 201, Xeomin) in the treatment of blepharospasm-a randomized trial. Mov Disord 2011;26:1521-1528.
13. Wabbels B, Jost WH, Roggenkamper P. Difficulties with differentiating botulinum toxin treatment effects in essential blepharospasm. J Neural Transm 2011;118:925-943.
14. Cano SJ, Warner TT, Linacre JM, et al. Capturing the true burden of dystonia on patients: the Cervical Dystonia Impact Profile (CDIP-58). Neurology 2004;63:1629-1633.
15. Cano SJ, Hobart JC, Edwards M, et al. CDIP-58 can measure the impact of botulinum toxin treatment in cervical dystonia. Neurology 2006;67:2230-2232.
16. Zetterberg L, Aquilonius SM, Lindmark B. Impact of dystonia on quality of life and health in a Swedish population. Acta Neurol Scand 2009;119:376-382.
17. Jankovic J, Adler CH, Charles PD, et al. Rationale and design of a prospective study: Cervical Dystonia Patient Registry for Observation of OnaBotulinumtoxinA Efficacy (CD PROBE). BMC Neurol 2011;11:140.
18. Sethi KD, Rodriguez R, Olayinka B. Satisfaction with botulinum toxin treatment: a cross-sectional survey of patients with cervical dystonia. J Med Econ 2012;15:419-423.
19. Cano SJ, Warner TT, Thompson AJ, Bhatia KP, Fitzpatrick R, Hobart JC. The cervical dystonia impact profile (CDIP-58): can a Rasch developed patient reported outcome measure satisfy traditional psychometric criteria? Health Qual Life Outcomes 2008;6:58.
20. Consky ES, Lang AE. Clinical assessments of patients with cervical dystonia. In: Jankovic J, Hallett M, editors. Therapy with botulinum toxin. New York, NY: Marcel Dekker; 1994:211-237.
21. Comella CL, Stebbins GT, Goetz CG, Chmura TA, Bressman SB, Lang AE. Teaching tape for the motor section of the Toronto Western Spasmodic Torticollis Scale. Mov Disord 1997;12:570-575.
22. Lalli S, Piacentini S, Franzini A, et al. Epidural premotor cortical stimulation in primary focal dystonia: clinical and 18F-fluoro deoxyglucose positron emission tomography open study. Mov Disord 2012;27:533-538.
23. Capelle HH, Blahak C, Schrader C, et al. Bilateral deep brain stimulation for cervical dystonia in patients with previous peripheral surgery. Mov Disord 2012;27:301-304.
24. Skogseid IM, Ramm-Pettersen J, Volkmann J, Kerty E, Dietrichs E, Roste GK. Good long-term efficacy of pallidal stimulation in cervical dystonia: a prospective, observer-blinded study. Eur J Neurol 2012;19:610-615.
25. Comella CL, Jankovic J, Truong DD, Hanschmann A, Grafe S. Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN((R)), botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia. J Neurol Sci 2011;308:103-109.
26. Ostrem JL, Racine CA, Glass GA, et al. Subthalamic nucleus deep brain stimulation in primary cervical dystonia. Neurology 2011;76:870-878.
27. Chinnapongse R, Pappert EJ, Evatt M, Freeman A, Birmingham W. An open-label, sequential dose-escalation, safety, and tolerability study of rimabotulinumtoxinb in subjects with cervical dystonia. Int J Neurosci 2010;120:703-710.
28. Cacciola F, Farah JO, Eldridge PR, Byrne P, Varma TK. Bilateral deep brain stimulation for cervical dystonia: long-term outcome in a series of 10 patients. Neurosurgery 2010;67:957-963.
29. Lew MF, Chinnapongse R, Zhang Y, Corliss M. RimabotulinumtoxinB effects on pain associated with cervical dystonia: results of placebo and comparator-controlled studies. Int J Neurosci 2010;120:298-300.
30. Truong D, Brodsky M, Lew M, et al. Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia. Parkinsonism Relat Disord 2010;16:316-323.
31. Quagliato EM, Carelli EF, Viana MA. A prospective, randomized, double-blind study comparing the efficacy and safety of type a botulinum toxins botox and prosigne in the treatment of cervical dystonia. Clin Neuropharmacol 2010;33:22-26.
32. Moro E, Piboolnurak P, Arenovich T, Hung SW, Poon YY, Lozano AM. Pallidal stimulation in cervical dystonia: clinical implications of acute changes in stimulation parameters. Eur J Neurol 2009;16:506-512.
33. Berman BD, Starr PA, Marks WJ, Ostrem JL. Induction of bradykinesia with pallidal deep brain stimulation in patients with cranial-cervical dystonia. Stereotact Funct Neurosurg 2009;87:37-44.
34. Pretto TE, Dalvi A, Kang UJ, Penn RD. A prospective blinded evaluation of deep brain stimulation for the treatment of secondary dystonia and primary torticollis syndromes. J Neurosurg 2008;109:405-409.
35. Pinsker MO, Volkmann J, Falk D, et al. Electrode implantation for deep brain stimulation in dystonia: a fast spin-echo inversion-recovery sequence technique for direct stereotactic targeting of the GPI. Zentralbl Neurochir 2008;69:71-75.
36. Pappert EJ, Germanson T. Botulinum toxin type B vs. type A in toxin-naive patients with cervical dystonia: Randomized, double-blind, noninferiority trial. Mov Disord 2008;23:510-517.
37. Kiss ZH, Doig-Beyaert K, Eliasziw M, Tsui J, Haffenden A, Suchowersky O. The Canadian multicentre study of deep brain stimulation for cervical dystonia. Brain 2007;130:2879-2886.
38. Skogseid IM, Malt UF, Roislien J, Kerty E. Determinants and status of quality of life after long-term botulinum toxin therapy for cervical dystonia. Eur J Neurol 2007;14:1129-1137.
39. Comella CL, Jankovic J, Shannon KM, et al. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology 2005;65:1423-1429.
40. Ondo WG, Gollomp S, Galvez-Jimenez N. A pilot study of botulinum toxin A for headache in cervical dystonia. Headache 2005;45:1073-1077.
41. Factor SA, Molho ES, Evans S, Feustel PJ. Efficacy and safety of repeated doses of botulinum toxin type B in type A resistant and responsive cervical dystonia. Mov Disord 2005;20:1152-1160.
42. Bihari K. Safety, effectiveness, and duration of effect of BOTOX after switching from Dysport for blepharospasm, cervical dystonia, and hemifacial spasm dystonia, and hemifacial spasm. Curr Med Res Opin 2005;21:433-438.
43. Dressler D, Bigalke H. Botulinum toxin type B de novo therapy of cervical dystonia: frequency of antibody induced therapy failure. J Neurol 2005;252:904-907.
44. Truong D, Duane DD, Jankovic J, et al. Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study. Mov Disord 2005;20:783-791.
45. Kiss ZH, Doig K, Eliasziw M, Ranawaya R, Suchowersky O. The Canadian multicenter trial of pallidal deep brain stimulation for cervical dystonia: preliminary results in three patients. Neurosurg Focus 2004;17:E5.
46. Eltahawy HA, Saint-Cyr J, Giladi N, Lang AE, Lozano AM. Primary dystonia is more responsive than secondary dystonia to pallidal interventions: outcome after pallidotomy or pallidal deep brain stimulation. Neurosurgery 2004;54:613-619.
47. Meyer CH. Outcome of selective peripheral denervation for cervical dystonia. Stereotact Funct Neurosurg 2001;77:44-47.
48. Naumann M, Yakovleff A, Durif F. A randomized, double-masked, crossover comparison of the efficacy and safety of botulinum toxin type A produced from the original bulk toxin source and current bulk toxin source for the treatment of cervical dystonia. J Neurol 2002;249:57-63.
49. Munchau A, Palmer JD, Dressler D, et al. Prospective study of selective peripheral denervation for botulinum-toxin resistant patients with cervical dystonia. Brain 2001;124:769-783.
50. Lucetti C, Nuti A, Gambaccini G, et al. Mexiletine in the treatment of torticollis and generalized dystonia. Clin Neuropharmacol 2000;23:186-189.
51. Brashear A, Lew MF, Dykstra DD, et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia. Neurology 1999;53:1439-1446.
52. Brin MF, Lew MF, Adler CH, et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A- resistant cervical dystonia. Neurology 1999;53:1431-1438.
53. Krauss JK, Toups EG, Jankovic J, Grossman RG. Symptomatic and functional outcome of surgical treatment of cervical dystonia. J Neurol Neurosurg Psychiatry 1997;63:642-648.
54. Truong DD, Cullis PA, O'Brien CF, Koller M, Villegas TP, Wallace JD. BotB (botulinum toxin type B): evaluation of safety and tolerability in botulinum toxin type A-resistant cervical dystonia patients (preliminary study). Mov Disord 1997;12:772-775.
55. Lew MF, Adornato BT, Duane DD, et al. Botulinum toxin type B: a double-blind, placebo-controlled, safety and efficacy study in cervical dystonia. Neurology 1997;49:701-707.
56. Brans JW, Lindeboom R, Snoek JW, et al. Botulinum toxin versus trihexyphenidyl in cervical dystonia: a prospective, randomized, double-blind controlled trial. Neurology 1996;46:1066-1072.
57. Brans JW, Lindeboom R, Aramideh M, Speelman JD. Long-term effect of botulinum toxin on impairment and functional health in cervical dystonia. Neurology 1998;50:1461-1463.
58. Ranoux D, Gury C, Fondarai J, Mas JL, Zuber M. Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia. J Neurol Neurosurg Psychiatry 2002;72:459-462.
59. Tarsy D. Comparison of clinical rating scales in treatment of cervical dystonia with botulinum toxin. Mov Disord 1997;12:100-102.
60. Muller J, Wissel J, Kemmler G, et al. Craniocervical dystonia questionnaire (CDQ-24): development and validation of a disease-specific quality of life instrument. J Neurol Neurosurg Psychiatry 2004;75:749-753.
61. Tepavcevic DK, Svetel M, Pekmezovic T, Petrovic I, Kostic VS. Craniocervical Dystonia Questionnaire (CDQ-24): validation and cross-cultural adaptation in Serbian patients. Coll Antropol 2009;33:1185-1189.
62. Zetterberg L, Halvorsen K, Farnstrand C, Aquilonius SM, Lindmark B. Physiotherapy in cervical dystonia: six experimental single-case studies. Physiother Theory Pract 2008;24:275-290.
63. Jacobson BH, Johnson A, Grywalski C, et al. The Voice Handicap Index (VHI): development and validation. Am J Speech Lang Pathol 1997;6:66-70.
64. Woisard V, Bodin S, Puech M. [The Voice Handicap Index: impact of the translation in French on the validation]. Le "Voice Handicap Index": impact de la traduction française sur la validation. Rev Laryngol Otol Rhinol (Bord) 2004;125:307-312. [French].
65. Rosen CA, Murry T, Zinn A, Zullo T, Sonbolian M. Voice handicap index change following treatment of voice disorders. J Voice 2000;14:619-623.
66. Courey MS, Garrett CG, Billante CR, et al. Outcomes assessment following treatment of spasmodic dysphonia with botulinum toxin. Ann Otol Rhinol Laryngol 2000;109:819-822.
67. Spector BC, Netterville JL, Billante C, Clary J, Reinisch L, Smith TL. Quality-of-life assessment in patients with unilateral vocal cord paralysis. Otolaryngol Head Neck Surg 2001;125:176-182.
68. Benninger MS, Gardner G, Grywalski C. Outcomes of botulinum toxin treatment for patients with spasmodic dysphonia. Arch Otolaryngol Head Neck Surg 2001;127:1083-1085.
69. Lee L, Daughton S, Scheer S, et al. Use of acupuncture for the treatment of adductor spasmodic dysphonia: a preliminary investigation. J Voice 2003;17:411-424.
70. Chhetri DK, Mendelsohn AH, Blumin JH, Berke GS. Long-term follow-up results of selective laryngeal adductor denervation-reinnervation surgery for adductor spasmodic dysphonia. Laryngoscope 2006;116:635-642.
71. Tsuji DH, Chrispim FS, Imamura R, Sennes LU, Hachiya A. Impact in vocal quality in partial myectomy and neurectomy endoscopic of thyroarytenoid muscle in patients with adductor spasmodic dysphonia. Braz J Otorhinolaryngol 2006;72:261-266.
72. Hussain A, Shakeel M. Selective lateral laser thyroarytenoid myotomy for adductor spasmodic dysphonia. J Laryngol Otol 2010;124:886-891.
73. Tsuji DH, Takahashi MT, Imamura R, Hachiya A, Sennes LU. Endoscopic laser thyroarytenoid myoneurectomy in patients with adductor spasmodic dysphonia: a pilot study on long-term outcome on voice quality. J Voice 2012;26:666-612.
74. Novakovic D, Waters HH, D'Elia JB, Blitzer A. Botulinum toxin treatment of adductor spasmodic dysphonia: longitudinal functional outcomes. Laryngoscope 2011;121:606-612.
75. Morzaria S, Damrose EJ. A comparison of the VHI, VHI-10, and V-RQOL for measuring the effect of botox therapy in adductor spasmodic dysphonia. J Voice 2012;26:378-380.
76. Carding PN, Horsley IA, Docherty GJ. A study of the effectiveness of voice therapy in the treatment of 45 patients with nonorganic dysphonia. J Voice 1999;13:72-104.
77. Webb AL, Carding PN, Deary IJ, MacKenzie K, Steen IN, Wilson JA. Optimising outcome assessment of voice interventions. I: Reliability and validity of three self-reported scales. J Laryngol Otol 2007;121:763-767.
78. Steen IN, MacKenzie K, Carding PN, Webb A, Deary IJ, Wilson JA. Optimising outcome assessment of voice interventions. II: Sensitivity to change of self-reported and observer-rated measures. J Laryngol Otol 2008;122:46-51.
79. MacKenzie K, Millar A, Wilson JA, Sellars C, Deary IJ. Is voice therapy an effective treatment for dysphonia? A randomised controlled trial. BMJ 2001;323:658-661.
80. Rattenbury HJ, Carding PN, Finn P. Evaluating the effectiveness and efficiency of voice therapy using transnasal flexible laryngoscopy: a randomized controlled trial. J Voice 2004;18:522-533.
81. Meek P, Carding PN, Howard DH, Lennard TW. Voice change following thyroid and parathyroid surgery. J Voice 2008;22:765-772.
82. Deary IJ, Webb A, MacKenzie K, Wilson JA, Carding PN. Short, self-report voice symptom scales: psychometric characteristics of the voice handicap index-10 and the vocal performance questionnaire. Otolaryngol Head Neck Surg 2004;131:232-235.
83. Burke RE, Fahn S, Marsden CD, Bressman SB, Moskowitz C, Friedman J. Validity and reliability of a rating scale for the primary torsion dystonias. Neurology 1985;35:73-77.
84. Kim JP, Chang WS, Chang JW. The long-term surgical outcomes of secondary hemidystonia associated with post-traumatic brain injury. Acta Neurochir (Wien) 2012;154:823-830.
85. Cif L, Gonzalez-Martinez V, Vasques X, et al. Staged implantation of multiple electrodes in the internal globus pallidus in the treatment of primary generalized dystonia. J Neurosurg 2012;116:1144-1152.
86. Panov F, Tagliati M, Ozelius LJ, et al. Pallidal deep brain stimulation for DYT6 dystonia. J Neurol Neurosurg Psychiatry 2012;83:182-187.
87. Sobstyl M, Zabek M, Dzierzecki S, Koziara H, Mossakowski Z. Chronic bilateral pallidal stimulation in patients with generalized primary dystonia - multi-contact cathodal stimulation is superior to bipolar stimulation mode. Preliminary results. Neurol Neurochir Pol 2011;45:252-259.
88. Schrader C, Capelle HH, Kinfe TM, et al. GPi-DBS may induce a hypokinetic gait disorder with freezing of gait in patients with dystonia. Neurology 2011;77:483-488.
89. Limotai N, Go C, Oyama G, et al. Mixed results for GPi-DBS in the treatment of cranio-facial and cranio-cervical dystonia symptoms. J Neurol 2011;258:2069-2074.
90. Valalik I, Jobbagy A, Bognar L, Csokay A. Effectiveness of unilateral pallidotomy for Meige syndrome confirmed by motion analysis. Stereotact Funct Neurosurg 2011;89:157-161.
91. Isaias IU, Volkmann J, Kupsch A, et al. Factors predicting protracted improvement after pallidal DBS for primary dystonia: the role of age and disease duration. J Neurol 2011;258:1469-1476.
92. Reese R, Gruber D, Schoenecker T, et al. Long-term clinical outcome in Meige syndrome treated with internal pallidum deep brain stimulation. Mov Disord 2011;26:691-698.
93. Azoulay-Zyss J, Roze E, Welter ML, et al. Bilateral deep brain stimulation of the pallidum for myoclonus-dystonia due to epsilon-sarcoglycan mutations: a pilot study. Arch Neurol 2011;68:94-98.
94. Sako W, Morigaki R, Mizobuchi Y, et al. Bilateral pallidal deep brain stimulation in primary Meige syndrome. Parkinsonism Relat Disord 2011;17:12--125.
95. Gruber D, Kuhn AA, Schoenecker T, et al. Pallidal and thalamic deep brain stimulation in myoclonus-dystonia. Mov Disord 2010;25:1733-1743.
96. Vidailhet M, Yelnik J, Lagrange C, et al. Bilateral pallidal deep brain stimulation for the treatment of patients with dystonia-choreoathetosis cerebral palsy: a prospective pilot study. Lancet Neurol 2009;8:709-717.
97. Gruber D, Trottenberg T, Kivi A, et al. Long-term effects of pallidal deep brain stimulation in tardive dystonia. Neurology 2009;73:53-58.
98. Sensi M, Cavallo MA, Quatrale R, et al. Pallidal stimulation for segmental dystonia: long term follow up of 11 consecutive patients. Mov Disord 2009;24:1829-1835.
99. Vasques X, Cif L, Gonzalez V, Nicholson C, Coubes P. Factors predicting improvement in primary generalized dystonia treated by pallidal deep brain stimulation. Mov Disord 2009;24:846-853.
100. Sako W, Goto S, Shimazu H, et al. Bilateral deep brain stimulation of the globus pallidus internus in tardive dystonia. Mov Disord 2008;23:1929-1931.
101. Hamasaki T, Yamada K, Kuratsu J. Hemidystonia secondary to thalamic hemorrhage treated with GPi stimulation. Mov Disord 2008;23:1762-1766.
102. Sobstyl M, Zabek M, Koziara H, Dzierzecki S. Chronic bilateral pallidal stimulation in a patient with DYT-1 positive primary generalized dystonia. A long-term follow-up study. Neurol Neurochir Pol 2008;42:50-54.
103. Houeto JL, Yelnik J, Bardinet E, et al. Acute deep-brain stimulation of the internal and external globus pallidus in primary dystonia: functional mapping of the pallidum. Arch Neurol 2007;64:1281-1286.
104. Alterman RL, Miravite J, Weisz D, Shils JL, Bressman SB, Tagliati M. Sixty Hertz pallidal deep brain stimulation for primary torsion dystonia. Neurology 2007;69:681-688.
105. Kleiner-Fisman G, Liang GS, Moberg PJ, et al. Subthalamic nucleus deep brain stimulation for severe idiopathic dystonia: impact on severity, neuropsychological status, and quality of life. J Neurosurg 2007;107:29-36.
106. Ostrem JL, Marks WJ Jr, Volz MM, Heath SL, Starr PA. Pallidal deep brain stimulation in patients with cranial-cervical dystonia (Meige syndrome). Mov Disord 2007;22:1885-1891.
107. Kupsch A, Benecke R, Muller J, et al. Pallidal deep-brain stimulation in primary generalized or segmental dystonia. N Engl J Med 2006;355:1978-1990.
108. Coubes P, Cif L, El Fertit H, et al. Electrical stimulation of the globus pallidus internus in patients with primary generalized dystonia: long-term results. J Neurosurg 2004;101:189-194.
109. Katayama Y, Fukaya C, Kobayashi K, Oshima H, Yamamoto T. Chronic stimulation of the globus pallidus internus for control of primary generalized dystonia. Acta Neurochir Suppl 2003;87:125-128.
110. Air EL, Ostrem JL, Sanger TD, Starr PA. Deep brain stimulation in children: experience and technical pearls. J Neurosurg Pediatr 2011;8:566-574.
111. Haridas A, Tagliati M, Osborn I, et al. Pallidal deep brain stimulation for primary dystonia in children. Neurosurgery 2011;68:738-743.
112. Timmermann L, Pauls KA, Wieland K, et al. Dystonia in neurodegeneration with brain iron accumulation: outcome of bilateral pallidal stimulation. Brain 2010;133:701-712.
113. Borggraefe I, Mehrkens JH, Telegravciska M, Berweck S, Botzel K, Heinen F. Bilateral pallidal stimulation in children and adolescents with primary generalized dystonia-report of six patients and literature-based analysis of predictive outcomes variables. Brain Dev 2010;32:223-228.
114. Borggraefe I, Boetzel K, Boehmer J, et al. Return to participation - significant improvement after bilateral pallidal stimulation in rapidly progressive DYT-1 dystonia. Neuropediatrics 2008;39:239-242.
115. Comella CL, Leurgans S, Wuu J, Stebbins GT, Chmura T. Rating scales for dystonia: a multicenter assessment. Mov Disord 2003;18:303-312.